ONCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ONCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Oncternal Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was $-3.27.
During the past 3 years, the average EBITDA Per Share Growth Rate was 6.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 36.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 36.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Oncternal Therapeutics was 62.10% per year. The lowest was -147.20% per year. And the median was 11.70% per year.
For the Biotechnology subindustry, Oncternal Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Oncternal Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Oncternal Therapeutics (NAS:ONCT) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Thank you for viewing the detailed overview of Oncternal Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Gunnar F. Kaufmann | officer: Chief Scientific Officer | C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Salim Yazji | officer: Chief Medical Officer | 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
James B Breitmeyer | director, officer: President, CEO | |
Richard G Vincent | officer: Chief Financial Officer | C/O WOMEN FIRST HEALTH CARE, 5355 MIRA SORRENTO PLACE STE. 700, SAN DIEGO CA 92121-3825 |
Chase C. Leavitt | officer: General Counsel/Secretary | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Jill Desimone | director | C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110 |
Rajesh Krishnan | officer: Chief Technology Officer | 12230 EL CAMINO, SUITE 300, SAN DIEGO CA 92130 |
Jinzhu Phd Chen | director | 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Michael G Carter | director | C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008 |
Daniel L Kisner | director | 2292 FARADAY AVENUE, CARLSBAD CA 92008 |
Shanghai Pharmaceuticals Holding Co., Ltd. | 10 percent owner | C/O ONCTEMAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Shanghai Pharmaceuticals (hk) Investment Ltd | 10 percent owner | C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Shanghai Pharmaceutical (usa) Inc. | 10 percent owner | C/O ONCTERNAL THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS ROAD #821, SAN DIEGO CA 92130-2122 |
Hazel M Aker | officer: General Counsel | C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008 |
Man Cho | director | C/O ONCTERNAL THERAPEUTICS, INC., SUITE 300, SAN DIEGO CA 92130 |
From GuruFocus
By Marketwired • 08-03-2023
By Value_Insider Value_Insider • 12-01-2022
By Value_Insider Value_Insider • 11-03-2022
By Stock market mentor Stock market mentor • 01-03-2023
By sperokesalga sperokesalga • 05-31-2023
By Marketwired • 10-05-2023
By Marketwired • 08-10-2023
By Value_Insider Value_Insider • 12-10-2022
By sperokesalga sperokesalga • 03-27-2023
By sperokesalga sperokesalga • 04-13-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.